Vaccinating against Helicobacter pylori infection
Authors:
- 8 February 2011
- journal article
- review article
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 8 (3) , 133-140
Abstract
Helicobacter pylori infection of the gastric mucosa remains a cause of significant morbidity and mortality almost 30 years after its discovery. H. pylori infection can lead to several gastric maladies, including gastric cancer, and although antimicrobial therapies for the infection exist, the cost of treatment for gastric cancer and the prognosis of individuals who present with this disease make vaccine development a cost effective alternative to bacterial eradication. Experimental mucosal and systemic H. pylori vaccines in mice significantly reduce bacterial load and sometimes provide sterilizing immunity. Clinical trials of oral vaccines consisting of H. pylori proteins with bacterial exotoxin adjuvants or live attenuated bacterial vectors expressing H. pylori proteins induce adaptive immune mechanisms but fail to consistently reduce bacterial load. Clinical trials and murine studies demonstrate that where H. pylori is killed, either spontaneously or following vaccination, the host demonstrated cellular immunity. Improved efficacy of vaccines may be achieved in new trials of vaccine formulations that include multiple antigens and use methods to optimize cellular immunity. Unfortunately, the industrial sponsors that served as the primary engine for much of the previous animal and human research have withdrawn their support. A renewed or expanded commitment from the biotechnology or pharmaceutical industry that could exploit recent advances in our understanding of the host immune response to H. pylori is necessary for the advancement of an H. pylori vaccine.Keywords
This publication has 76 references indexed in Scilit:
- Considering Global Vaccination against Helicobacter pyloriSouthern Medical Journal, 2010
- Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxinVaccine, 2010
- Helicobacter pylori vaccines.2010
- Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccinesGut, 2008
- Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental InterfacesImmunity, 2008
- The Recurrence of Helicobacter pylori Infection: Incidence and Variables Influencing It. A Critical ReviewAmerican Journal of Gastroenterology, 2005
- Immunisation against gastric infection with Helicobacter species: First step in the prophylaxis of gastric cancer?Zentralblatt für Bakteriologie, 1993
- Blood lymphocyte proliferation, cytokine secretion and appearance of T cells with activation surface markers in cultures with Helicobacter pylori. Comparison of the responses of subjects with and without antibodies to H. pyloriClinical and Experimental Immunology, 1991
- Helicobacter pylori induces lymphocyte activation in peripheral blood culturesClinical and Experimental Immunology, 1990
- Prevalence of Helicobacter pylori Infection and Histologic Gastritis in Asymptomatic PersonsNew England Journal of Medicine, 1989